Personal history of breast cancer as a significant risk factor for endometrial serous carcinoma in women aged 55 years old or younger

International Journal of Cancer

Volumn 128, Issue 4, 2011, Pages 763-770

  Liang, Sharon X ^a   Pearl, Micheal ^a   Liang, Shu ^b   Xiang, Li ^c   Jia, Lin ^c,g   Yang, Binlie ^d   Fadare, Oluwole ^e   Schwartz, Peter E ^f   Chambers, Setsuko K ^c   Kong, Beihua ^g   Zheng, Wenxin ^c,d,g  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b Oregon State Department of Correction   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d Gongli Hospital   (China)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g SHANDONG UNIVERSITY   (China)

Author keywords

breast cancer; endometrial serous carcinoma; high risk; uterine papillary serous carcinoma

Indexed keywords

TAMOXIFEN;

ADULT; AGE DISTRIBUTION; AGED; BREAST CANCER; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DRUG USE; ENDOMETRIUM CARCINOMA; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL HISTORY; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; TUMOR VOLUME;

ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MIDDLE AGED; PROGNOSIS; RISK FACTORS;

EID: 78650617304     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25395     Document Type: Review

References (48)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ,. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Bristow RE,. Endometrial cancer. Curr Opin Oncol 1999; 11: 388-93.
3. Sherman ME,. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13: 295-308.
4. Burke TW, Fowler Jr.W.C., Morrow CP,. Clinical aspects of risk in women with endometrial carcinoma. J Cell Biochem Suppl 1995; 23: 131-6.
5. Robboy SJ, Bentley RC, Krigman H, Silverberg SG, Norris HJ, Zaino RJ,. Synoptic reports in gynecologic pathology. Int J Gynecol Pathol 1994; 13: 161-74.
6. Carcangiu ML, Tan LK, Chambers JT,. Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 1997; 21: 1507-14.
7. Hamilton CA, Kapp DS, Chan JK,. Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol 2008; 20: 26-33.
8. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ,. Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16: 600-10.
9. Silva EG, Jenkins R,. Serous carcinoma in endometrial polyps. Mod Pathol 1990; 3: 120-8.
10. Bailar JC III,. The incidence of independent tumors among uterine cancer patients. Cancer 1963; 16: 842-53.
11. Curtis R, Ron E, Hankey B, Hoover R,. New malignancies following breast cancer. NCI, SEER Registries 1973-2000;Ch 7: 181-205.
12. Yager JD,. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000: 67-73.
13. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE,. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000; 356: 881-7.
14. Cohen I,. Endometrial pathologies associated with postmenopausal tamoxifen treatment. Gynecol Oncol 2004; 94: 256-66.
15. Deligdisch L, Kalir T, Cohen CJ, de Latour M, Le Bouedec G, Penault-Llorca F,. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000; 78: 181-6.
16. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994; 343: 448-52.
17. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ,. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994; 55: 164-8.
18. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM,. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994; 86: 527-37. (Pubitemid 24111008)
19. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML,. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993; 11: 485-90.
20. Silva EG, Tornos C, Malpica A, Mitchell MF,. Uterine neoplasms in patients treated with tamoxifen. J Cell Biochem Suppl 1995; 23: 179-83.
21. Liang S, Pearl M, Tornos C, Kelly M, Schwartz P, T Z, W Z,. Endometrial serous carcinoma has a strong association with breast cancer, particularly in patients younger than 56 years of age. United States and Canadian Association of Pathology annual meeting 2007.
22. Slomovitz BM, Burke TW, Eifel P, Ramondetta LM, Silva EG, Jhingran A, Oh JC, Atkinson EN, Broaddus RR, Gershenson DM, Lu KH,. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases [see comment]. Gynecol Oncol 2003; 91: 463-9.
23. Chan JK, Manuel MR, Cheung MK, Osann K, Husain A, Teng NN, Rao A, Carlson RW, Whittemore AS,. Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? Gynecol Oncol 2006; 102: 508-12.
24. Geisler JP, Sorosky JI, Duong HL, Buekers TE, Geisler MJ, Sood AK, Anderson B, Buller RE,. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol 2001; 83: 501-3.
25. Elit L, Pal T, Goshen R, Jernstrom H, Ackerman I, Fyles A, Carey M, Mitchell M, Aube J, Narod SA,. Familial and hormonal risk factors for papillary serous uterine cancer. Eur J Gynaecol Oncol 2002; 23: 187-90.
26. Lavie O, Hornreich G, Ben-Arie A, Rennert G, Cohen Y, Keidar R, Sagi S, Lahad EL, Auslander R, Beller U,. BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol 2004; 92: 521-4.
27. Hornreich G, Beller U, Lavie O, Renbaum P, Cohen Y, Levy-Lahad E,. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol 1999; 75: 300-4.
28. Lavie O, Hornreich G, Ben Arie A, Renbaum P, Levy-Lahad E, Beller U,. BRCA1 germline mutations in women with uterine serous papillary carcinoma. Obstet Gynecol 2000; 96: 28-32.
29. Gehrig PA, Bae-Jump VL, Boggess JF, Groben PA, Fowler WC Jr, Van Le L,. Association between uterine serous carcinoma and breast cancer. Gynecol Oncol 2004; 94: 208-11.
30. Cohn DE, Resnick KE, Ramirez NC, Morrison CD,. Advanced endometrial cancer with serous metastasis in a 17-year-old. Gynecol Oncol 2006; 101: 356-9.
31. Hendrickson M, Ross J, Eifel P, Martinez A, Kempson R,. Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 1982; 6: 93-108.
32. Stanford JL, Greenberg RS,. Breast cancer incidence in young women by estrogen receptor status and race. Am J Public Health 1989; 79: 71-3.
33. Arai M, Utsunomiya J, Miki Y,. Familial breast and ovarian cancers. Int J Clin Oncol 2004; 9: 270-82.
34. Hall HI, Jamison P, Weir HK,. Second primary ovarian cancer among women diagnosed previously with cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 995-9.
35. Brinton L, lacey JT, Sherman M,. Epidemiology of gynecologic cancers. In: Principles and practice of gynecologic oncology, Eds:, Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, 2004, 4th edn. 3-32.
36. Gustafson S, Zbuk KM, Scacheri C, Eng C,. Cowden syndrome. Semin Oncol 2007; 34: 428-34.
37. Akashi M, Koeffler HP,. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility. Clin Obstet Gynecol 1998; 41: 172-99.
38. Bignell GR, Barfoot R, Seal S, Collins N, Warren W, Stratton MR,. Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res 1998; 58: 1384-6.
39. Swift M, Reitnauer PJ, Morrell D, Chase CL,. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med 1987; 316: 1289-94.
40. Sherman M, Bur ME, Kurman RJ,. p53 in endometrial cancers and its putative precursors: evidence for diverse pathways of tumorigenesis. Human Pathol 1995; 26: 1268-74.
41. Fadare O, Zheng W,. Endometrial glandular dysplasia (EmGD): morphologically and biologically distinctive putative precursor lesions of Type II endometrial cancers. Diagn Pathol 2008; 3: 6.
42. Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, Zheng W,. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 2008; 14: 2263-9.
43. Jarboe EA, Pizer ES, Miron A, Monte N, Mutter GL, Crum CP,. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod Pathol 2009; 22: 345-50.
44. Zhang X, Liang SX, Jia L, Chen N, Fadare O, Schwartz PE, Kong B, Zheng W,. Molecular identification of "latent precancers" for endometrial serous carcinoma in benign-appearing endometrium. Am J Pathol 2009; 174: 2000-6.
45. Von W, Lindblom A, Gronberg H, Rosenquist Z,. A hypothesis-generating search for new genetic breast cancer syndromes-a study in 803 Swedish families. Hereditary Can Clin Prac 2007; 5: 17-24.
46. Mutter GL,. Diagnosis of premalignant endometrial disease. J Clin Pathol 2002; 55: 326-31.
47. Purdie DM, Green AC,. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001; 15: 341-54.
48. Wang W, Do V, Hogg R, Wain G, Brand A, Bull C, Stenlake A, Gebski V,. Uterine papillary serous carcinoma: patterns of failure and survival. Aust N Z J Obstet Gynaecol 2009; 49: 419-25.